RBC Capital analyst Brian Abrahams lowered the firm’s price target on IGM Biosciences to $8 from $11 and keeps a Sector Perform rating on the shares. IGM’s major pipeline initiatives remain on track, with multiple trials for mCRC ongoing with aplitabart, and several trials for SLE and RA ongoing with imvotamab, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IGMS: